Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Drug Shortage Strategy: Enforcement Discretion, Patient Public Relations

This article was originally published in The Pink Sheet Daily

Executive Summary

Rapid approval of a new, preservative-free generic methotrexate and permission to import an unapproved version of doxorubicin touted at press conference as FDA emphasizes the success of administrative efforts.

You may also be interested in...



FDA Envisions Flexible Approach To Expanded Use Of Accelerated Approval

In its desktop reference guidance on the four expedited regulatory pathways, FDA broadens its view of when an investigational drug fills an “unmet medical need” and guides sponsors through the use of intermediate clinical endpoints as a basis for accelerated approval.

Drug Shortages Give Ben Venue Relief In FDA Consent Decree

The consent decree permits the company to continue to manufacture more than 100 drugs, 20 of which are on FDA’s current drug shortage list. Ben Venue must prove compliance with good manufacturing practice requirements before it can manufacture its other drugs.

Drug Shortages Give Ben Venue Relief In FDA Consent Decree

The consent decree permits the company to continue to manufacture more than 100 drugs, 20 of which are on FDA’s current drug shortage list. Ben Venue must prove compliance with good manufacturing practice requirements before it can manufacture its other drugs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS073779

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel